Riot Platforms, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Riot Platforms, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $647.44M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $376.66M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $280.68M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $259.17M | Feb 28, 2025 |
| FY2022 | Sep 30, 2022 | $46.29M | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | $72.95M | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | $79.79M | Mar 2, 2023 |
| FY2023 | Dec 31, 2021 | $213.24M | Feb 23, 2024 |
| FY2022 | Sep 30, 2021 | $64.81M | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | $34.35M | Mar 2, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $6.4K | Mar 31, 2017 |
| FY2015 | Dec 31, 2015 | $5.0K | Mar 23, 2016 |
| FY2015 | Sep 30, 2015 | $43.0K | Mar 23, 2016 |
| FY2015 | Jun 30, 2015 | $16.0K | Mar 23, 2016 |
| FY2015 | Mar 31, 2015 | $7.0K | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | $51.0K | Mar 23, 2016 |
| FY2015 | Sep 30, 2014 | $24.0K | Mar 23, 2016 |
| FY2015 | Mar 31, 2014 | $20.0K | Mar 23, 2016 |
| FY2015 | Dec 31, 2013 | $34.9K | Mar 23, 2016 |
| FY2014 | Sep 30, 2013 | $35.0K | Mar 30, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($663.18M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $109.40M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($49.47M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($509.55M) | Feb 28, 2025 |
| FY2022 | Sep 30, 2022 | ($32.44M) | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | ($353.56M) | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | $36.58M | Mar 2, 2023 |
| FY2023 | Dec 31, 2021 | ($15.44M) | Feb 23, 2024 |
| FY2022 | Sep 30, 2021 | ($22.04M) | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | $19.01M | Mar 2, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($622.17M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $153.59M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($63.05M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($512.70M) | Feb 28, 2025 |
| FY2022 | Sep 30, 2022 | ($35.88M) | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | ($353.24M) | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | $38.86M | Mar 2, 2023 |
| FY2023 | Dec 31, 2021 | ($29.87M) | Feb 23, 2024 |
| FY2022 | Sep 30, 2021 | ($10.84M) | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | ($5.45M) | Mar 2, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $20.0K | Apr 17, 2018 |
| FY2017 | Dec 31, 2016 | $249.2K | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $2.16M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $4.03M | Mar 23, 2016 |
| FY2015 | Dec 31, 2013 | $6.71M | Mar 23, 2016 |
| FY2014 | Dec 31, 2012 | $3.84M | Mar 30, 2015 |
| FY2013 | Dec 31, 2011 | $5.67M | Mar 28, 2014 |
| FY2012 | Dec 31, 2010 | $6.11M | Mar 26, 2013 |
| FY2011 | Dec 31, 2009 | $9.29M | Mar 16, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $298.78M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $266.92M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $100.35M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $67.45M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $87.43M | Feb 23, 2024 |
| FY2023 | Dec 31, 2020 | $87.43M | Feb 23, 2024 |
| FY2021 | Dec 31, 2019 | $9.16M | Nov 23, 2022 |
| FY2019 | Dec 31, 2018 | $20.86M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $7.31M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | $4.41M | Apr 17, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($572.93M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($255.05M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $33.09M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $530.0K | Feb 28, 2025 |
| FY2022 | Sep 30, 2022 | ($964.0K) | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | ($14.39M) | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | ($45.32M) | Mar 2, 2023 |
| FY2023 | Dec 31, 2021 | ($86.08M) | Feb 23, 2024 |
| FY2022 | Sep 30, 2021 | ($60.87M) | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | ($27.16M) | Mar 2, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.38M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $240.34M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $193.70M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $148.41M | Feb 28, 2025 |
| FY2022 | Sep 30, 2022 | $129.67M | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | $77.40M | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | $37.08M | Mar 2, 2023 |
| FY2023 | Dec 31, 2021 | $147.12M | Feb 23, 2024 |
| FY2022 | Sep 30, 2021 | $78.86M | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | $7.13M | Mar 2, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.94B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.94B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $2.05B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.32B | Feb 23, 2024 |
| FY2022 | Sep 30, 2022 | $1.45B | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | $1.44B | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | $1.54B | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | $1.52B | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $943.57M | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | $902.23M | Mar 2, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $791.62M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $163.06M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $168.52M | Feb 23, 2024 |
| FY2022 | Sep 30, 2022 | $154.25M | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | $147.66M | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | $162.07M | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | $173.62M | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $184.09M | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | $192.21M | Mar 2, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.86B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.14B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.89B | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $1.15B | Mar 2, 2026 |
| FY2024 | Dec 31, 2021 | $1.35B | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $275.63M | Feb 23, 2024 |
| FY2020 | Dec 31, 2019 | $26.24M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.79M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $48.87M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | $14.92M | Apr 17, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.50M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $121.89M | Mar 2, 2026 |
| FY2022 | Mar 31, 2022 | $335.65M | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | $335.56M | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $253.74M | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | $253.91M | Mar 2, 2023 |
| FY2018 | Dec 31, 2017 | $1.19M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | $387.2K | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $448.0K | Mar 31, 2017 |
| FY2016 | Dec 31, 2014 | $448.0K | Mar 31, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.35B) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($690.42M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($799.82M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($756.34M) | Feb 23, 2024 |
| FY2022 | Sep 30, 2022 | ($596.21M) | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | ($563.77M) | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | ($210.21M) | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | ($246.79M) | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | ($229.22M) | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | ($207.19M) | Mar 2, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.52M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $277.86M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $597.17M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $230.33M | Mar 2, 2026 |
| FY2022 | Sep 30, 2022 | $254.97M | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | $270.48M | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | $113.58M | Mar 2, 2023 |
| FY2024 | Dec 31, 2021 | $312.32M | Feb 28, 2025 |
| FY2022 | Sep 30, 2021 | $57.88M | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | $147.18M | Mar 2, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $840.80M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $584.63M | Mar 2, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 28, 2025 |
| FY2022 | Sep 30, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | (2) | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 2, 2023 |
| FY2023 | Dec 31, 2021 | 0 | Feb 23, 2024 |
| FY2022 | Sep 30, 2021 | 0 | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 2, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 28, 2025 |
| FY2022 | Sep 30, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | (2) | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 2, 2023 |
| FY2023 | Dec 31, 2021 | 0 | Feb 23, 2024 |
| FY2022 | Sep 30, 2021 | 0 | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 2, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 371.58M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 344.89M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 230.84M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 167.75M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 116.75M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 78.52M | Nov 23, 2022 |
| FY2020 | Dec 31, 2019 | 25.08M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 14.52M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 11.62M | Apr 2, 2019 |
| FY2016 | Dec 31, 2016 | 4.50M | Mar 31, 2017 |